2026 Q2 - tulosraportti
69 päivää sitten
‧32 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 8 523 | ||
| 1 477 | ||
| 330 | ||
| 48 193 | ||
| 6 010 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 19.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 20.8. | ||
2026 Q1 - tulosraportti 21.5. | ||
2025 Q4 - tulosraportti 26.3. | ||
2025 Q3 - tulosraportti 19.11.2025 | ||
2025 Q2 - tulosraportti 15.8.2025 |
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
·20 t sittenASN Kidney week in Denver was just held from Oct 21-25. And here KDIGO was on the field with various presentations of their upcoming new guidelines. From ChatGPT follows the following: Guideline for Acute Kidney Injury (AKI) and Acute Kidney Disease (AKD) • Status: The brand new updates were officially presented and reviewed during ASN Kidney Week in October 2026. • Expected release: The full, final guideline (KDIGO 2026 AKI/AKD Guideline) will be officially released at the end of 2026. Subclinical AKI and "Supra-clinical" biomarkers A major theme at the conference in relation to the new KDIGO 2026 guidelines was the concept of subclinical AKI. This covers a condition where a patient has normal creatinine (and thereby technically does not meet the old criteria for renal failure), but has sky-high NGAL levels. Studies show that these patients have just as poor prognoses and high mortality as those with visible renal failure, which is why NGAL is now integrated to catch these "blind spots" in the clinic. So maybe this is the year that BioPorto finally gives us the Christmas present that we have been waiting for in 15-20 years 🙏
·1 päivä sitten · MuokattuThen you probably have to dig into your pockets again, if you do not want to be diluted Se https://borsen.dk/nyheder/investor/bioporto-vil-undga-endnu-en-kapitalrejsning-investor-ser-millionhul?b_source=borsen&b_medium=row_0&b_campaign=share_link_article Does anyone have an idea what their alternatives are? Bank loans? Bonds?
Now that some of the steam has gone out of it, it would be appropriate for CB to arrange a webcast so we can get certainty on whether they have changed their mind regarding a new share issue or if they have a plan to avoid it and in that case which one?- ·23.10.Bioporto is making hay while the sun shines, I have lost count of how many trade fairs and conferences they have attended this year. I can see on their website that they are going to 3 more trade fairs this year. https://bioporto.com/events/For 5-6 years you have written with the same great enthusiasm about all the trade fairs and conferences they participate in. But you have looked at the price chart, right? It is only just a bit above the lowest it has ever been, so unfortunately there is nothing to suggest that they are gaining any particular value from those trade fairs. When you are in the kitchen, don't you also taste the food first before you add salt?
·23.10.It is very strange that 2 trades at 16.59 of respectively 2 and 7 pcs help to get the price from 1.025 to 0.994 - what is happening here ?
·21.10.It is very interesting that professor, Dr. Med, Jun Oh’s independent presentation on October 7, 2026 at BioPorto in Copenhagen is now available. He presented NGAL as a necessary paradigm shift in everyday clinical practice: Until now, the global KDIGO guidelines (which have not been updated since 2012) have effectively overlooked biomarkers. Without an official KDIGO recommendation, the NGAL test has merely been seen as a "nice-to-have" supplementary research tool rather than a clinical requirement. That is only changing now with the new guidelines in late 2026. * Catalyst for adoption: When an independent KOL of his caliber adopts a product and speaks warmly of it, it creates a "snowball effect". Other hospitals and physicians worldwide trust a respected professor colleague far more than a sales signal from BioPorto itself, which accelerates adoption. * Strengthening the commercial case: His open interest and data support, as well as thorough assessment of the need where his slides show the need for NGAL (the size of the potential market for NGAL), validate the market potential toward major distribution partners (such as Roche and Beckman Coulter). It removes commercial skepticism and shows investors that BioPorto's test is not just "a smart idea", but a real tool that is already being integrated at top European hospitals. He assesses the need for the NGAL test as critical and acute. He has emphasized this by stating that he now uses the NGAL test routinely in his own department to catch kidney injuries in time and save patients from dialysis. Dr. Jun Oh is precisely the type of top clinician whose professional stamping of approval pharmaceutical and diagnostics companies dream of having behind them: * International heavyweight: He is a highly respected name at international medical conferences and is a Council Member in the two leading professional societies: European Society for Paediatric Nephrology (ESPN) and Gesellschaft für Pädiatrische Nephrologie (GPN). * Expert in European networks: Dr. Jun Oh has been appointed as official clinical expert and coordinator in the European Reference Network for Rare Kidney Diseases (ERKNet). This network sets the standard for the treatment of rare kidney diseases throughout Europe. * Focus on guidelines: Due to his broad engagement in randomized clinical trials and patient registries, he is one of the key figures whose professional assessments carry heavy weight when new clinical guidelines (including KDIGO) are formulated and presented at conferences. His absolute specialty is paediatric nephrology (kidney diseases in children) and organ transplantations. He leads one of Europe's largest transplantation programs for infants and children. He has published over 100 original scientific articles (“peer reviewed publications”). *The presentation: https://www.inderes.dk/en/videos/bioporto-from-reaction-to-prevention-in-aki?utm_source=nordnet&utm_medium=integrationPreston, you write among other things: "It removes commercial skepticism and shows investors that BioPorto's test is not just "a smart idea", but a real tool that is already being integrated into top European hospitals". When I look at the stock, I see no sign that investors' skepticism has been removed. The stock market has always been known for being many months ahead of almost any event, and yet, even though in this chat again and again and for a long time now it has been stated that it is almost a mere formality for KDIGO to change their recommendations in favor of ngal and BioPorto, I see no sign of increased volume and buying interest, and the stock price, well, it certainly hasn't been rising, rather the opposite. Where do you yourself concretely see actual signs that investors' skepticism has been removed?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 415 038 | 415 038 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 415 038 | 415 038 | 0 | 0 |
2026 Q2 - tulosraportti
69 päivää sitten
‧32 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·20 t sittenASN Kidney week in Denver was just held from Oct 21-25. And here KDIGO was on the field with various presentations of their upcoming new guidelines. From ChatGPT follows the following: Guideline for Acute Kidney Injury (AKI) and Acute Kidney Disease (AKD) • Status: The brand new updates were officially presented and reviewed during ASN Kidney Week in October 2026. • Expected release: The full, final guideline (KDIGO 2026 AKI/AKD Guideline) will be officially released at the end of 2026. Subclinical AKI and "Supra-clinical" biomarkers A major theme at the conference in relation to the new KDIGO 2026 guidelines was the concept of subclinical AKI. This covers a condition where a patient has normal creatinine (and thereby technically does not meet the old criteria for renal failure), but has sky-high NGAL levels. Studies show that these patients have just as poor prognoses and high mortality as those with visible renal failure, which is why NGAL is now integrated to catch these "blind spots" in the clinic. So maybe this is the year that BioPorto finally gives us the Christmas present that we have been waiting for in 15-20 years 🙏
- ·1 päivä sitten · MuokattuThen you probably have to dig into your pockets again, if you do not want to be diluted Se https://borsen.dk/nyheder/investor/bioporto-vil-undga-endnu-en-kapitalrejsning-investor-ser-millionhul?b_source=borsen&b_medium=row_0&b_campaign=share_link_article Does anyone have an idea what their alternatives are? Bank loans? Bonds?Now that some of the steam has gone out of it, it would be appropriate for CB to arrange a webcast so we can get certainty on whether they have changed their mind regarding a new share issue or if they have a plan to avoid it and in that case which one?
- ·23.10.Bioporto is making hay while the sun shines, I have lost count of how many trade fairs and conferences they have attended this year. I can see on their website that they are going to 3 more trade fairs this year. https://bioporto.com/events/For 5-6 years you have written with the same great enthusiasm about all the trade fairs and conferences they participate in. But you have looked at the price chart, right? It is only just a bit above the lowest it has ever been, so unfortunately there is nothing to suggest that they are gaining any particular value from those trade fairs. When you are in the kitchen, don't you also taste the food first before you add salt?
- ·23.10.It is very strange that 2 trades at 16.59 of respectively 2 and 7 pcs help to get the price from 1.025 to 0.994 - what is happening here ?
- ·21.10.It is very interesting that professor, Dr. Med, Jun Oh’s independent presentation on October 7, 2026 at BioPorto in Copenhagen is now available. He presented NGAL as a necessary paradigm shift in everyday clinical practice: Until now, the global KDIGO guidelines (which have not been updated since 2012) have effectively overlooked biomarkers. Without an official KDIGO recommendation, the NGAL test has merely been seen as a "nice-to-have" supplementary research tool rather than a clinical requirement. That is only changing now with the new guidelines in late 2026. * Catalyst for adoption: When an independent KOL of his caliber adopts a product and speaks warmly of it, it creates a "snowball effect". Other hospitals and physicians worldwide trust a respected professor colleague far more than a sales signal from BioPorto itself, which accelerates adoption. * Strengthening the commercial case: His open interest and data support, as well as thorough assessment of the need where his slides show the need for NGAL (the size of the potential market for NGAL), validate the market potential toward major distribution partners (such as Roche and Beckman Coulter). It removes commercial skepticism and shows investors that BioPorto's test is not just "a smart idea", but a real tool that is already being integrated at top European hospitals. He assesses the need for the NGAL test as critical and acute. He has emphasized this by stating that he now uses the NGAL test routinely in his own department to catch kidney injuries in time and save patients from dialysis. Dr. Jun Oh is precisely the type of top clinician whose professional stamping of approval pharmaceutical and diagnostics companies dream of having behind them: * International heavyweight: He is a highly respected name at international medical conferences and is a Council Member in the two leading professional societies: European Society for Paediatric Nephrology (ESPN) and Gesellschaft für Pädiatrische Nephrologie (GPN). * Expert in European networks: Dr. Jun Oh has been appointed as official clinical expert and coordinator in the European Reference Network for Rare Kidney Diseases (ERKNet). This network sets the standard for the treatment of rare kidney diseases throughout Europe. * Focus on guidelines: Due to his broad engagement in randomized clinical trials and patient registries, he is one of the key figures whose professional assessments carry heavy weight when new clinical guidelines (including KDIGO) are formulated and presented at conferences. His absolute specialty is paediatric nephrology (kidney diseases in children) and organ transplantations. He leads one of Europe's largest transplantation programs for infants and children. He has published over 100 original scientific articles (“peer reviewed publications”). *The presentation: https://www.inderes.dk/en/videos/bioporto-from-reaction-to-prevention-in-aki?utm_source=nordnet&utm_medium=integrationPreston, you write among other things: "It removes commercial skepticism and shows investors that BioPorto's test is not just "a smart idea", but a real tool that is already being integrated into top European hospitals". When I look at the stock, I see no sign that investors' skepticism has been removed. The stock market has always been known for being many months ahead of almost any event, and yet, even though in this chat again and again and for a long time now it has been stated that it is almost a mere formality for KDIGO to change their recommendations in favor of ngal and BioPorto, I see no sign of increased volume and buying interest, and the stock price, well, it certainly hasn't been rising, rather the opposite. Where do you yourself concretely see actual signs that investors' skepticism has been removed?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 8 523 | ||
| 1 477 | ||
| 330 | ||
| 48 193 | ||
| 6 010 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 19.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 20.8. | ||
2026 Q1 - tulosraportti 21.5. | ||
2025 Q4 - tulosraportti 26.3. | ||
2025 Q3 - tulosraportti 19.11.2025 | ||
2025 Q2 - tulosraportti 15.8.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 415 038 | 415 038 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 415 038 | 415 038 | 0 | 0 |
2026 Q2 - tulosraportti
69 päivää sitten
‧32 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 19.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 20.8. | ||
2026 Q1 - tulosraportti 21.5. | ||
2025 Q4 - tulosraportti 26.3. | ||
2025 Q3 - tulosraportti 19.11.2025 | ||
2025 Q2 - tulosraportti 15.8.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·20 t sittenASN Kidney week in Denver was just held from Oct 21-25. And here KDIGO was on the field with various presentations of their upcoming new guidelines. From ChatGPT follows the following: Guideline for Acute Kidney Injury (AKI) and Acute Kidney Disease (AKD) • Status: The brand new updates were officially presented and reviewed during ASN Kidney Week in October 2026. • Expected release: The full, final guideline (KDIGO 2026 AKI/AKD Guideline) will be officially released at the end of 2026. Subclinical AKI and "Supra-clinical" biomarkers A major theme at the conference in relation to the new KDIGO 2026 guidelines was the concept of subclinical AKI. This covers a condition where a patient has normal creatinine (and thereby technically does not meet the old criteria for renal failure), but has sky-high NGAL levels. Studies show that these patients have just as poor prognoses and high mortality as those with visible renal failure, which is why NGAL is now integrated to catch these "blind spots" in the clinic. So maybe this is the year that BioPorto finally gives us the Christmas present that we have been waiting for in 15-20 years 🙏
- ·1 päivä sitten · MuokattuThen you probably have to dig into your pockets again, if you do not want to be diluted Se https://borsen.dk/nyheder/investor/bioporto-vil-undga-endnu-en-kapitalrejsning-investor-ser-millionhul?b_source=borsen&b_medium=row_0&b_campaign=share_link_article Does anyone have an idea what their alternatives are? Bank loans? Bonds?Now that some of the steam has gone out of it, it would be appropriate for CB to arrange a webcast so we can get certainty on whether they have changed their mind regarding a new share issue or if they have a plan to avoid it and in that case which one?
- ·23.10.Bioporto is making hay while the sun shines, I have lost count of how many trade fairs and conferences they have attended this year. I can see on their website that they are going to 3 more trade fairs this year. https://bioporto.com/events/For 5-6 years you have written with the same great enthusiasm about all the trade fairs and conferences they participate in. But you have looked at the price chart, right? It is only just a bit above the lowest it has ever been, so unfortunately there is nothing to suggest that they are gaining any particular value from those trade fairs. When you are in the kitchen, don't you also taste the food first before you add salt?
- ·23.10.It is very strange that 2 trades at 16.59 of respectively 2 and 7 pcs help to get the price from 1.025 to 0.994 - what is happening here ?
- ·21.10.It is very interesting that professor, Dr. Med, Jun Oh’s independent presentation on October 7, 2026 at BioPorto in Copenhagen is now available. He presented NGAL as a necessary paradigm shift in everyday clinical practice: Until now, the global KDIGO guidelines (which have not been updated since 2012) have effectively overlooked biomarkers. Without an official KDIGO recommendation, the NGAL test has merely been seen as a "nice-to-have" supplementary research tool rather than a clinical requirement. That is only changing now with the new guidelines in late 2026. * Catalyst for adoption: When an independent KOL of his caliber adopts a product and speaks warmly of it, it creates a "snowball effect". Other hospitals and physicians worldwide trust a respected professor colleague far more than a sales signal from BioPorto itself, which accelerates adoption. * Strengthening the commercial case: His open interest and data support, as well as thorough assessment of the need where his slides show the need for NGAL (the size of the potential market for NGAL), validate the market potential toward major distribution partners (such as Roche and Beckman Coulter). It removes commercial skepticism and shows investors that BioPorto's test is not just "a smart idea", but a real tool that is already being integrated at top European hospitals. He assesses the need for the NGAL test as critical and acute. He has emphasized this by stating that he now uses the NGAL test routinely in his own department to catch kidney injuries in time and save patients from dialysis. Dr. Jun Oh is precisely the type of top clinician whose professional stamping of approval pharmaceutical and diagnostics companies dream of having behind them: * International heavyweight: He is a highly respected name at international medical conferences and is a Council Member in the two leading professional societies: European Society for Paediatric Nephrology (ESPN) and Gesellschaft für Pädiatrische Nephrologie (GPN). * Expert in European networks: Dr. Jun Oh has been appointed as official clinical expert and coordinator in the European Reference Network for Rare Kidney Diseases (ERKNet). This network sets the standard for the treatment of rare kidney diseases throughout Europe. * Focus on guidelines: Due to his broad engagement in randomized clinical trials and patient registries, he is one of the key figures whose professional assessments carry heavy weight when new clinical guidelines (including KDIGO) are formulated and presented at conferences. His absolute specialty is paediatric nephrology (kidney diseases in children) and organ transplantations. He leads one of Europe's largest transplantation programs for infants and children. He has published over 100 original scientific articles (“peer reviewed publications”). *The presentation: https://www.inderes.dk/en/videos/bioporto-from-reaction-to-prevention-in-aki?utm_source=nordnet&utm_medium=integrationPreston, you write among other things: "It removes commercial skepticism and shows investors that BioPorto's test is not just "a smart idea", but a real tool that is already being integrated into top European hospitals". When I look at the stock, I see no sign that investors' skepticism has been removed. The stock market has always been known for being many months ahead of almost any event, and yet, even though in this chat again and again and for a long time now it has been stated that it is almost a mere formality for KDIGO to change their recommendations in favor of ngal and BioPorto, I see no sign of increased volume and buying interest, and the stock price, well, it certainly hasn't been rising, rather the opposite. Where do you yourself concretely see actual signs that investors' skepticism has been removed?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 8 523 | ||
| 1 477 | ||
| 330 | ||
| 48 193 | ||
| 6 010 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 415 038 | 415 038 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 415 038 | 415 038 | 0 | 0 |